The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 2, 2008, Pages 236-242

  Kim, K A ^a   Park, P W ^b   Hong, S J ^a   Park, J Y ^a  

^a Korea University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYOMEPRAZOLE; CLOPIDOGREL; CYTOCHROME P450 2C19; OMEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG METABOLISM; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HETEROZYGOUS EXTENSIVE METABOLIZER; HOMOZYGOSITY; HOMOZYGOTE; HOMOZYGOUS EXTENSIVE METABOLIZER; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INDIVIDUALIZATION; LOADING DRUG DOSE; MALE; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT RESPONSE;

ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; KOREA; MALE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 45249088224     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.20     Document Type: Article

References (42)

1. Gurbel, P.A., Bliden, K.P., Hiatt, B.L. & O'Connor, C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003).
2. Muller, I., Besta, F., Schulz, C., Massberg, S., Schonig, A. & Gawaz, M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. 89, 783-787 (2003).
3. Gurbel, P.A. & Bliden, K.P. Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. 91, 1123-1125 (2003).
4. Nguyen, T.A., Diodati, J.G. & Pharand, C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. 45, 1157-1164 (2005).
5. Michos, E.D., Ardehali, R., Blumenthal, R.S., Lange, R.A. & Ardehali, H. Aspirin and clopidogrel resistance. Mayo Clin. Proc. 81, 518-526 (2006).
6. Pereillo, J.M. et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. 30, 1288-1295 (2002).
7. Savi, P. et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 84, 891-896 (2000).
8. Savi, P., Labouret, C., Delesque, N., Guette, F., Lupker, J. & Herbert, J.M. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. 283, 379-383 (2001).
9. Lau, W.C. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109, 166-171 (2004).
10. Suh, J.W. et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174, 1715-1722 (2006).
11. Hulot, J.S. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244-2247 (2006).
12. Brandt, J.T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
13. Fontana, P., Hulot, J.S., De Moerloose, P. & Gaussem, P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J. Thromb. Haemost. 5, 2153-2155 (2007).
14. Giusti, B. et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17, 1057-1064 (2007).
15. Kurihara, A., Hagihara, K., Kazui, M., Ozeki, T., Farid, N.A. & Ikeda, T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsbile for two oxidation steps involved in the active metabolite formation. Drug Metab. Rev. 37, 99 (2005).
16. Desta, Z., Zhao, X., Shin, J.G. & Flockhart, D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958 (2002).
17. Wang, T.H., Bhatt, D.L. & Topol, E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J. 27, 647-654 (2006).
18. Schroeder, W.S., Ghobrial, L. & Gandhi, P.J. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J. Thromb. Thrombolysis 22, 139-150 (2006).
19. Brandt, J.T. et al. CYP2C19*2 Polymorphism contributes to a diminished pharmacodynamic response to clopidogrel. J. Am. Coll. Cardiol. 47 (suppl. 1), 380A (2006).
20. Farid, N.A. et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol Ther. 81, 735-741 (2007).
21. Lau, W.C. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107, 32-37 (2003).
22. Clarke, T.A. & Waskell, L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 31, 53-59 (2003).
23. Fontana, P., Senouf, D. & Mach, F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19()2 allele on clopidogrel responsiveness. Thromb. Res. 121, 463-468 (2007).
24. Kim, K.A. et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Clin. Pharmacol. Ther. 72, 90-99 (2002).
25. Gonzalez, H.M. et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J. Clin. Pharmacol. 43, 1211-1215 (2003).
26. Gilard, M., Arnaud, B., Le Gal, G., Abgrall, J.F. & Boschat, J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J. Thromb. Haemost. 4, 2508-2509 (2006).
27. Snoep, J.D., Hovens, M.M., Eikenboom, J.C., van der Bom, J.G., Jukema, J.W. & Huisman, M.V. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221-231 (2007).
28. Weerakkody, G.J., Brandt, J.T., Payne, C.D., Jakubowski, J.A., Naganuma, H. & Winters, K.J. Clopidogrel poor responders: an objective definition based on Bayesian classification. Platelets 18, 428-435 (2007).
29. Flockhart, D.A. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. Clin. Pharmacokinet. 29 (suppl. 1), 45-52 (1995).
30. Muller, I. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85, 92-93 (2001).
31. Angiolillo, D.J. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25, 1903-1910 (2004).
32. Kim, K.A., Park, P.W. & Park, J.Y. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur. J. Clin. Pharmacol. in press (2008).
33. Smith, S.M. et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 17, 250-258 (2006).
34. Aoyama, T. et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 264, 10388-10395 (1989).
35. Human Cytochrome P450 Allele Nomenclature Committee. CYP3A4 allele nomenclature. 〈http://www.imm.ki.se/CYPalleles/cyp3a4.htm〉. Accessed 29 November 2007.
36. Shon, J.H. et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 12, 111-119 (2002).
37. Lainesse, A., Ozalp, Y., Wong, H. & Alpan, R.S. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung 54, 600-604 (2004).
38. Angiolillo, D.J. et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res. 115, 101-108 (2005).
39. Angiolillo, D.J. et al. 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul. Fibrinolysis 15, 427-433 (2004).
40. Kimura, M. et al. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. Br. J. Clin. Pharmacol. 47, 115-119 (1999).
41. Chang, M., Dahl, M.L., Tybring, G., Gotharson, E. & Bertilsson, L. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5, 358-363 (1995).
42. Rosemary, J., Adithan, C., Padmaja, N., Shashindran, C.H., Gerard, N. & Krishnamoorthy, R. The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur. J. Clin. Pharmacol. 61, 19-23 (2005).